Bachrodt Amy 4

What Happened

• Amy Bachrodt, SVP Finance at Maze Therapeutics, exercised options to acquire 2,500 shares at $10.42 each (cost $26,050) on April 1, 2026. On the same day she sold 2,200 shares at a weighted average $29.32 and 300 shares at a weighted average $30.34, receiving total gross proceeds of about $73,611. The Form 4 also shows a disposition of 2,500 shares at $0 (reported as a derivative disposition).

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 2, 2026 (timely).
• Option exercise: 2,500 shares acquired at $10.42 for $26,050.
• Open-market sales: 2,200 shares at $29.32 (weighted avg; prices ranged $28.85–$29.82) for $64,510; 300 shares at $30.34 (weighted avg; ranged $30.05–$30.50) for $9,101. Total gross sales ≈ $73,611.
• Derivative disposition: 2,500 shares reported disposed at $0. (This entry is shown separately on the Form 4 and is commonly used when shares are surrendered/withheld in connection with an option exercise or tax/withholding obligations.)
• Footnotes: One sale was executed under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (F1). Vesting schedule noted: options vest 1/48th monthly beginning Jan 1, 2025 (F4).
• Shares owned after transaction: not reported in the provided excerpt of the filing.

Context

• This was an option exercise combined with immediate open-market sales. The exercise at $10.42 followed by sales near $29–$30 resulted in a material spread between strike and sale prices; proceeds from the sales were about $73.6K. The presence of a 10b5-1 plan note indicates at least some sales were pre-planned rather than discretionary.